Commentary

Video

TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC

Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.

Pharmacy Times® interviewed Shirish Gadgeel, MD, chief of the Division of Hematology/Oncology at Henry Ford Cancer Institute, on a session at the European Society for Medical Oncology Congress 2024 in Barcelona, Spain, discussing an integrated analysis of the regional TRUST-I study (NCT04395677) and global TRUST-II study (NCT04919811). The studies looked at the efficacy and safety of taletrectinib (AB-106; AnHeart Therapeutics) in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC). The analysis showed that taletrectinib elicited high and durable overall response rates with favorable tolerability in the treatment of ROS1+ NSCLC.

Pharmacy Times: Can you discuss the combined analysis of the TRUST-I and TRUST-II trial results?

TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC

Image Credit: © mi_viri - stock.adobe.com

Shirish Gadgeel, MD: So, there were data presented—and actually, what was presented about talatrectinib was a combined analysis of TRUST-I and TRUST-II—and I think the most sort of pleasantly surprising data from that combined analysis was that the median progression-free survival exceeded 40 months, coming up to close to 4 years. I think in [NSCLC] in the advanced stage, that is quite remarkable when you compare it to other datasets from other subsets of [NSCLC]. So, I think that the biggest, [most] impressive data that was presented of that combined analysis. In addition, the tolerability of the drug seems to be fairly good. I don't have personal experience with the drug, but the data that was presented [shows that] the drug appears to be fairly well tolerated. And I think that this could be a very good option for us for patients if this drug gets FDA approved.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards